老年晚期CKD患者在初级与肾脏专科照护中的指南依从性
这项基于常规医疗数据的 population-based 研究纳入2015–2024年间1969例≥65岁、eGFR<30 ml/min/1.73m2的CKD 4–5期患者,评估十三项质量指标的指南依从性。61.2%患者在初级保健管理,其年龄更大且更多被视为衰弱;各指标依从性在肾脏专科普遍更高,RAAS抑制剂使用率分别为56.9%与84.4%。
要点
- 多数老年CKD 4–5期患者(61.2%)在初级保健管理,指南依从性总体低于肾脏专科。
- 初级保健中白蛋白尿监测覆盖仅47.8%随访时间,肾脏专科为65.2%。
- RAAS抑制剂使用率初级保健56.9%、肾脏专科84.4%;SGLT2抑制剂分别为4.3%与10.1%。
核心结论
- 多数老年CKD 4–5期患者在初级保健管理,指南依从性因照护场所而异。
- 合并糖尿病者依从性更高,提示结构化疾病管理可提升初级保健CKD指南依从性。
研究设计与样本
- 基于初级保健与医院常规医疗数据的人群研究,纳入2015–2024年间≥65岁、eGFR<30 ml/min/1.73m2的CKD患者共1969例。
- 采用十三项质量指标评估指南依从性,计算达标患者比例或依从照护覆盖的随访时间比例。
主要发现
- 1969例患者平均年龄81.8岁,中位eGFR 25 ml/min/1.73m2,61.2%在初级保健管理,该组更年长且更多被视为衰弱。
- 初级保健随访时间覆盖率:肾功能82.5%、白蛋白尿47.8%、血压76.6%、血红蛋白85.6%、LDL-胆固醇50.9%、合并糖尿病者HbA1c 68.3%。
- 肾脏专科对应覆盖率:肾功能86.8%、白蛋白尿65.2%、血压84.4%、血红蛋白97.5%、LDL-胆固醇68.3%、合并糖尿病者HbA1c 84.9%。
- 代谢并发症监测覆盖率初级保健28.4%–79.2%、肾脏专科73.6%–97.8%;RAAS抑制剂使用率56.9%与84.4%,SGLT2抑制剂4.3%与10.1%,两场所NSAIDs均<7%。
- 指南依从性不随社会经济状态或原籍国变化;初级保健中合并糖尿病者依从性更高。
临床怎么用
- 对老年CKD 4–5期患者,初级保健可承担管理,但需加强白蛋白尿、LDL-胆固醇及代谢并发症监测。
- 可借鉴糖尿病结构化疾病管理模式,提升初级保健对CKD指南的依从性。
- 肾脏专科应关注从初级保健转诊患者的RAAS抑制剂与SGLT2抑制剂使用优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older patients with chronic kidney disease (CKD) often experience relatively slow kidney function decline, suggesting that, despite meeting referral criteria, primary care management may be appropriate. We assessed guideline recommended CKD management in patients with CKD stage 4-5 across primary and nephrology care. METHODS: Population-based study using routine healthcare data from primary care and hospitals, including patients ≥ 65 years with incident or prevalent eGFR <30 ml/min/1.73m2 between 2015 and 2024. Guideline adherence was evaluated using thirteen quality indicators, calculated as the proportion of patients fulfilling these indicators or the proportion of follow-up time covered by adherent care. RESULTS: Of 1969 patients (mean age 81.8 years, median eGFR 25 ml/min/1.73m2), 61.2% were managed in primary care. These patients were older and were more often considered frail. In primary care, monitoring covered 82.5% of follow-up time for kidney function, 47.8% for albuminuria, 76.6% for blood pressure, 85.6% for haemoglobin, 50.9% for LDL-cholesterol and 68.3% for HbA1c among patients with diabetes. Corresponding estimates in nephrology care were 86.8%, 65.2%, 84.4%, 97.5%, 68.3% and 84.9%, respectively. Monitoring of metabolic complications, which falls beyond primary care guidelines, was 28.4%-79.2% in primary care and 73.6%-97.8% in nephrology care. RAAS inhibitors were prescribed in 56.9% (primary care) and 84.4% (nephrology care); SGLT2 inhibitors in 4.3% and 10.1%, and NSAIDs in both settings < 7%. Guideline adherence did not vary by socio-economic status or country of origin. In primary care, adherence was higher in patients with diabetes. CONCLUSION: The majority of older patients with CKD stage 4-5 are managed in primary care. Guideline adherence varied across care settings, which served substantially different patient populations. Higher adherence in patients with diabetes, typically enrolled in structured disease management programs, suggests that embedding similar structured approaches may enhance adherence to CKD guideline in primary care.
引用
- Jongejan M, Kist JM, Groeneveld J, et al. CKD-guideline adherence in primary and nephrology care for older patients with advanced CKD. Nephrol Dial Transplant. 2026. PMID: 42550475. doi:10.1093/ndt/gfag171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。